CoChat

The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.

Cost-effectiveness of psilocybin-assisted therapy for severe depression: exploratory findings from a decision analytic model

Open access

Abstract

Background: There is growing evidence to support the use of the psychedelic drug psilocybin for difficult-to-treat depression. This paper compares the cost-effectiveness of psilocybin-assisted psychotherapy (PAP) with conventional medication, cognitive behavioural therapy (CBT), and the combination of conventional medication and CBT. Methods: A decision model simulated patient events (response, remission, and relapse) following treatment. Data on probabilities, costs and quality-adjusted life years (QALYs) were derived from previous studies or from best estimates. Expected healthcare and societal costs and QALYs over a 6-month time period were calculated. Sensitivity analyses were used to address uncertainty in parameter estimates. Results: The expected healthcare cost of PAP varied from £6132 to £7652 depending on the price of psilocybin. This compares to £3528 for conventional medication alone, £4250 for CBT alone, and £4197 for their combination. QALYs were highest for psilocybin (0.310), followed by CBT alone (0.283), conventional medication alone (0.278), and their combination (0.287). Psilocybin was shown to be cost-effective compared to the other therapies when the cost of therapist support was reduced by 50% and the psilocybin price was reduced from its initial value to £400 to £800 per person. From a societal perspective, psilocybin had improved cost-effectiveness compared to a healthcare perspective. Conclusions: Psilocybin has the potential to be a cost-effective therapy for severe depression. This depends on the level of psychological support that is given to patients receiving psilocybin and the price of the drug itself. Further data on long-term outcomes are required to improve the evidence base.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1017/s0033291723001411

Cites

24 of 24 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1. Decision model to compare cost-effectiveness of psilocybin, SSRIs alone, cognitive behavioural therapy alone, and combined SSRIs and cognitive behavioural therapy.
Figure 1. Decision model to compare cost-effectiveness of psilocybin, SSRIs alone, cognitive behavioural therapy alone, and combined SSRIs and cognitive behavioural therapy.CC BY · PubMed Central
Figure 2. Incremental cost-effectiveness ratio of psilocybin compared to alternative therapies from a healthcare perspective.
Figure 2. Incremental cost-effectiveness ratio of psilocybin compared to alternative therapies from a healthcare perspective.CC BY · PubMed Central
Figure 3. Incremental cost-effectiveness ratio of psilocybin compared to alternative therapies from a societal perspective.
Figure 3. Incremental cost-effectiveness ratio of psilocybin compared to alternative therapies from a societal perspective.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 24 references

Research works printed but not linked: 4

  1. Shute, 2021, Rethinking psychedelics and mental health, Science News, 200, 2
  2. National Collaborating Centre for Mental Health. (2010). Depression: The treatment and management of depression in adults (Updated Edition). Leicester (UK): British Psychological Society.
  3. 2022, British National formulary 2022
  4. 2022, British National Formulary 2022

Cited by

See all 42

Metadata

Authors
McCrone, P., Fisher, H., Knight, C., Harding, R., Schlag, A. K., Nutt, D. J., & Neill, J. C.
Affiliations
  • University of Greenwich (GB)
  • University College London (GB)
  • Imperial College London (GB)
  • University of Manchester (GB)
Corresponding author
McCrone, Paul
Venue
Psychological Medicine
Published
2023-06-02
Volume
53
Issue
16
Pages
7619-7626
ISSN
  • 0033-2917 (ISSN-L)
  • 1469-8978
OpenAlex
W4379095570
Cited by
42
References
24
Citations by year
2026: 17 · 2025: 15 · 2024: 9 · 2023: 1
FWCI
12.15
Type
journal article
Language
en
Open access
Locations
  • Psychological Medicine (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Research Explorer (The University of Manchester) (publishedVersion, cc-by)
  • Greenwich Academic Literature Archive (University of Greenwich) (acceptedVersion)
Topics
  • Social Sciences › Psychology › Clinical Psychology › Psychedelics and Drug Studies
  • Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
Keywords
psilocybin-assisted therapy, severe depression, cost-effectiveness, psychedelic therapy, cognitive behavioral therapy, antidepressants, quality-adjusted life years, health care costs, drug pricing, difficult-to-treat depression, relapse
MeSH terms
Cost-Benefit Analysis, Depression, Major Depressive Disorder, Humans, Psilocybin, Psychotherapy, Quality-Adjusted Life Years

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Cost-effectiveness of psilocybin-assisted therapy for severe depression: exploratory findings from a decision analytic model. https://app.cochat.ai/papers/10.1017/s0033291723001411
The paper
McCrone, P., Fisher, H., Knight, C., Harding, R., Schlag, A. K., Nutt, D. J., & Neill, J. C. (2023). Cost-effectiveness of psilocybin-assisted therapy for severe depression: exploratory findings from a decision analytic model. Psychological Medicine. https://doi.org/10.1017/s0033291723001411

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.